<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39373844</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1934</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.</ArticleTitle><Pagination><StartPage>891</StartPage><EndPage>907</EndPage><MedlinePgn>891-907</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-024-01120-0</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Viloxazine ER (extended-release capsules; Qelbree<sup>®</sup>) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children (&gt; 6 years old) and adults. This phase 3 open-label extension to a pivotal phase 3, double-blind trial evaluated the long-term safety and continued efficacy of viloxazine ER in adults with ADHD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicenter, flexible-dose, open-label extension to a phase III, double-blind, placebo-controlled trial (NCT04016779). Viloxazine ER was initiated at 200 mg/day and adjusted (between 200 and 600 mg/day) to achieve optimal efficacy and tolerability. Trial enrollment was halted temporarily (24 March 2020 to 23 July 2020) due to the coronavirus disease 2019 (COVID-19) pandemic. Participants completing double-blind treatment during that time were offered delayed enrollment upon trial requalification. Safety outcomes were the primary objectives. Secondary objectives were efficacy outcomes, including the ADHD Investigator Symptom Rating Scale (AISRS), and were assessed relative to double-blind baseline (or trial re-entry baseline for those whose enrollment was delayed by the COVID-19 pandemic).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 159 participants (133 immediate and 26 delayed rollover) received viloxazine ER, with a mean exposure of 265 ± 254.9 days. Adverse events (AEs) included (&gt; 10% incidence) insomnia (13.8%), nausea (13.8%), headache (10.7%), and fatigue (10.1%). AEs led to discontinuation for 17.6% of participants [most commonly insomnia (2.5%), nausea (2.5%), and fatigue (1.9%)]. AISRS total score [baseline mean ± standard deviation (SD): 37.9 ± 6.3] improved by the first follow-up visit (-11.4 ± 9.5; week 2) with continued improvement at subsequent visits (last on-study visit: -18.2 ± 11.54). Similar patterns of improvement were seen for other measures of efficacy, including quality of life and executive function. Following initial dose optimization, most participants (73%) used viloxazine ER doses ≥ 400 mg/day, with 36% using doses of 600 mg/day.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term viloxazine ER use was well tolerated, with no new long-term safety findings. Improvements in ADHD symptoms and associated measures were sustained throughout trial participation. In total, 73% percent of adult participants in this long-term study used viloxazine ER doses of 400 mg or more during maintenance treatment.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov Identifier: NCT04143217.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Childress</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Lenard A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fry</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asubonteng</LastName><ForeName>Kobby</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado-Cruz</LastName><ForeName>Zulane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formella</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA. jrubin@supernus.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04143217</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>5I5Y2789ZF</RegistryNumber><NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002214">Capsules</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="Y">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Attention-deficit/hyperactivity disorder (ADHD) is common in children and adults and characterized by inattention, impulsivity, and hyperactivity that can substantially interfere with everyday life. On the basis of positive efficacy and safety results from clinical studies in children, adolescents, and adults, viloxazine ER (viloxazine extended-release capsules) received US Food and Drug Administration (FDA) approval as a new treatment for ADHD and is marketed under the brand name Qelbree® (Supernus Pharmaceuticals, Inc). Adults who participated in the short-term (6 weeks) double-blind study that eventually led to the FDA approval of viloxazine ER were invited to enroll in this open-label extension trial to monitor the medication’s long-term safety and continued efficacy. This study also provided a pathway for study participants to continue receiving viloxazine ER until its FDA approval and commercial availability. Participants in the study received viloxazine ER at dosages between 200 and 600 mg/day on the basis of symptom response and side effects (most used at least 400 mg/day). Viloxazine ER was demonstrated to have a good safety and tolerability profile. The most common side effects were insomnia (13.8%), nausea (13.8%), headache (10.7%), and fatigue (10.1%). Long-term treatment led to continued improvement in ADHD symptoms, quality of life, and executive function (executive function includes cognitive skills such as organizing and following through with tasks). The study results further support the continued use of viloxazine ER as a long-term treatment option for adults with ADHD.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></OtherAbstract><CoiStatement>A.C. has received research support from, served as a consultant or speaker for, or served on an advisory board for Aardvark, Adlon, Akili Interactive, Allergan, Alora, Arbor, Axsome, Aytu, Cingulate Therapeutics, Corium, Emalex, Ironshore, KemPharm, Lumos, Neurovance, Noven, Otsuka, Purdue, Rhodes, Sunovion, Takeda Pharmaceuticals, Tris, and Supernus Pharmaceuticals, Inc. A.J.C. has received research support from, served as a consultant or speaker for, or served on an advisory board for AbbVie (Allergan), Acadia, Aevi Genomic Medicine, Akili Interactive, Arbor Pharmaceuticals, Atentiv, Axsome, Boehringer Ingelheim, Biogen, BioXcel, Cerevel, Cingulate Therapeutics, Corium, Eli Lilly, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Karuna, KemPharm, LivaNova, Lundbeck, MedAvante-ProPhase, Neos Therapeutics (now Aytu BioPharma), Neumora, Neurocrine, NeuroSigma, Neurovance, NLS Pharma, Noven, Otsuka, Purdue Canada, Rhodes Pharmaceuticals, Relmada Therapeutics, Inc., Sage Therapeutics, Sumitomo (Sunovion), Supernus Pharmaceuticals, Inc., Takeda Pharmaceuticals (Shire), Teva, Thynk Health, Tris Pharma, and VistaGen. L.A.A. has received grant and research support from Otsuka, Takeda Pharmaceuticals, and Corium Pharmaceuticals; has served as a consultant to Bracket, Major League Baseball, the National Football League, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, Supernus Pharmaceuticals, Inc., and SUNY; and has received loyalty payments (as inventor) since 2004 from NYU for the license of adult ADHD scales and training materials. N.F., K.A., Z.M.C., A.E.F., and J.R. are employees of Supernus Pharmaceuticals, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373844</ArticleId><ArticleId IdType="pmc">PMC11486793</ArticleId><ArticleId IdType="doi">10.1007/s40263-024-01120-0</ArticleId><ArticleId IdType="pii">10.1007/s40263-024-01120-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.</Citation></Reference><Reference><Citation>Adamou M, Arif M, Asherson P, Aw TC, Bolea B, Coghill D, et al. Occupational issues of adults with ADHD. BMC Psychiatry. 2013;13:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3599848</ArticleId><ArticleId IdType="pubmed">23414364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjowall D, Thorell LB. Functional impairments in attention deficit hyperactivity disorder: the mediating role of neuropsychological functioning. Dev Neuropsychol. 2014;39(3):187–204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017272</ArticleId><ArticleId IdType="pubmed">24742310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuermaier ABM, Tucha L, Butzbach M, Weisbrod M, Aschenbrenner S, Tucha O. ADHD at the workplace: ADHD symptoms, diagnostic status, and work-related functioning. J Neural Transm (Vienna). 2021;128(7):1021–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295111</ArticleId><ArticleId IdType="pubmed">33528652</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15950004</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477889</ArticleId><ArticleId IdType="pubmed">29892054</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810708</ArticleId><ArticleId IdType="pubmed">34384227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6109107</ArticleId><ArticleId IdType="pubmed">30097390</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019;86(5):335–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697582</ArticleId><ArticleId IdType="pubmed">31155139</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021;11:04009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7916320</ArticleId><ArticleId IdType="pubmed">33692893</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe SE, Schulenberg JE, Wilens TE, Schepis TS, McCabe VV, Veliz PT. Prescription stimulant medical and nonmedical use among us secondary school students, 2005 to 2020. JAMA Netw Open. 2023;6(4): e238707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10114020</ArticleId><ArticleId IdType="pubmed">37071423</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine BMC. Balancing access to ADHD medication. BMC Med. 2023;21(1):217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10280932</ArticleId><ArticleId IdType="pubmed">37337160</ArticleId></ArticleIdList></Reference><Reference><Citation>Schein J, Childress A, Cloutier M, Desai U, Chin A, Simes M, et al. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. BMC Psychiatry. 2022;22(1):377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9164343</ArticleId><ArticleId IdType="pubmed">35659281</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions: U.S. Food &amp; Drug Administration; 2023 [Available from: https://www.fda.gov/media/168066/download?attachment.</Citation></Reference><Reference><Citation>Danielson ML, Bohm MK, Newsome K, Claussen AH, Kaminski JW, Grosse SD, et al. Trends in stimulant prescription fills among commercially insured children and adults—United States, 2016–2021. MMWR Morb Mortal Wkly Rep. 2023;72(13):327–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10078845</ArticleId><ArticleId IdType="pubmed">36995976</ArticleId></ArticleIdList></Reference><Reference><Citation>Qelbree® (viloxazine extended-release capsules). Prescribing Information. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf.</Citation></Reference><Reference><Citation>Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, et al. Viloxazine in the management of cns disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219567</ArticleId><ArticleId IdType="pubmed">34003459</ArticleId></ArticleIdList></Reference><Reference><Citation>Strattera® (atomoxetine capsules). Prescribing Information. 2022. Available at: https://pi.lilly.com/us/strattera-pi.pdf</Citation></Reference><Reference><Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473988</ArticleId><ArticleId IdType="pubmed">32943948</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Olivares J, Yegla B, Bymaster FP, Earnest J, Koch J, Yu C, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-deficit/hyperactivity disorder. J Exp Pharmacol. 2024;16:13–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799649</ArticleId><ArticleId IdType="pubmed">38249320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431845</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">25684070</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley HL, Kulkarni RS, Gosden J, Brammer RJ, Hackett D, Heal DJ. Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats. J Psychopharmacol. 2014;28(3):254–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24327450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily spn-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. Viloxazine: pediatric first approval. Paediatr Drugs. 2021;23(4):403–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10575801</ArticleId><ArticleId IdType="pubmed">34036533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244935</ArticleId><ArticleId IdType="pubmed">34181360</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, Controlled Trial. Clin Ther. 2021;43(4):684–700.</Citation><ArticleIdList><ArticleId IdType="pubmed">33750646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146561</ArticleId><ArticleId IdType="pubmed">34092822</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36(8):897–915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9328182</ArticleId><ArticleId IdType="pubmed">35896943</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939319</ArticleId><ArticleId IdType="pubmed">30924702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, Hiscock H, Sciberras E, Efron D. Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family. Arch Pediatr Adolesc Med. 2008;162(4):336–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391142</ArticleId></ArticleIdList></Reference><Reference><Citation>Brevik EJ, Lundervold AJ, Halmoy A, Posserud MB, Instanes JT, Bjorvatn B, et al. Prevalence and clinical correlates of insomnia in adults with attention-deficit hyperactivity disorder. Acta Psychiatr Scand. 2017;136(2):220–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28547881</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Balasundaram MK. Comment on: “A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention deficit/hyperactivity disorder.” CNS Drugs. 2022;36(12):1331–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">36331782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Hull JT, Liranso T, Fry N, Cutler AJ, Rubin J, et al. Authors’ Reply to Singh and Balasundaram: Comment on “A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder.” CNS Drugs. 2022;36(12):1333–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9712289</ArticleId><ArticleId IdType="pubmed">36331781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al. Evaluation of the effect of SPN-812 (viloxazine extended-release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):20m13395.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049804</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh JI. Drug-induced liver injury. Yeungnam Univ J Med. 2020;37(1):2–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986960</ArticleId><ArticleId IdType="pubmed">31661757</ArticleId></ArticleIdList></Reference><Reference><Citation>Viloxazine. National Institute of Diabetes and Digestive and Kidney Diseases LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD. 2021.</Citation></Reference><Reference><Citation>Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448861</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66(3):294–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766294</ArticleId></ArticleIdList></Reference><Reference><Citation>Data on file. A phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group flexible-dose study of the efficacy and safety of SPN-812 in adults with attention-deficit/hyperactivity disorder (ADHD). 2022.</Citation></Reference><Reference><Citation>Tanaka Y, Brod M, Lane JR, Upadhyaya H. What is a clinically relevant improvement in quality of life in adults with ADHD? J Atten Disord. 2019;23(1):65–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">25876607</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser AGR, Hull J, Maldonado-Cruz Z, Earnest J, Rubin J. Evaluating the impact of caffeine on the incidence of adverse events during treatment with viloxazine extended-release (Qelbree®) in adults with ADHD. CNS Spectr. 2023;28(2):234–5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>